The FDA granted Orphan Drug Designation for a drug developed by Crinetics Pharmaceuticals for the treatment of Congenital Adrenal Hyperplasia (CAH).
2 reports, 1 independent
Updated Aug 21
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Orphan Drug Designation for a drug developed by Crinetics Pharmaceuticals for the treatment of Congenital Adrenal Hyperplasia (CAH).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Crinetics Pharmaceuticals
company in San Diego, United States
Nothing else this week.
Related events
- Ensysce is listed on NASDAQ and received FDA Orphan Drug Designation for its CRPS therapy.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- FDA accepted Milestone's response to the Complete Response Letter (CRL).
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
Coverage
Newest first; wire copies grouped- GlobeNewswireCrinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Na
- GlobeNewswireCrinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™